We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+6.26%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$5.69B
AUM Growth
+$546M
(+11%)
Cap. Flow
+$263M
Cap. Flow
% of AUM
4.63%
Top 10 Holdings %
Top 10 Hldgs %
11.85%
Holding
1,134
New
196
Increased
491
Reduced
251
Closed
159
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$35.7M |
| 2 |
Merck
MRK
|
+$30.3M |
| 3 |
Microsoft
MSFT
|
+$22.4M |
| 4 |
Yum China
YUMC
|
+$17.6M |
| 5 |
Occidental Petroleum
OXY
|
+$17.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$36.5M |
| 2 |
Intel
INTC
|
+$32.4M |
| 3 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$17.1M |
| 4 |
NVR
NVR
|
+$16.3M |
| 5 |
Deere & Co
DE
|
+$16.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.48% |
| 2 | Financials | 17.92% |
| 3 | Industrials | 13.48% |
| 4 | Consumer Discretionary | 11.28% |
| 5 | Healthcare | 10.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FPRX
751
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $504K | 0.01% |
+22,990
| New | +$739K |
|
|
CDTX
752
DELISTED
Cidara Therapeutics
CDTX
| $503K | 0.01% |
3,696
+1,193
| +48% | +$181K |
|
|
SEAC
753
DELISTED
Seachange International Inc
SEAC
| $502K | 0.01% |
6,385
+1,669
| +35% | +$98.6K |
|
|
LTS
754
DELISTED
Ladenburg Thalmann Financial Services Inc
LTS
| $501K | 0.01% |
158,521
+33,434
| +27% | +$104K |
|
|
CALY
755
Callaway Golf Company
CALY
$3.26B
| $500K | 0.01% |
35,863
| – | – |
|
|
BLCM
756
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $498K | 0.01% |
+5,919
| New | +$580K |
|
757
Procter & Gamble
PG
$343B
| $495K | 0.01% |
5,392
+1,480
| +38% | +$133K |
|
758
Amkor Technology
AMKR
$16.1B
| $494K | 0.01% |
+49,171
| New | +$526K |
|
759
SunCoke Energy
SXC
$757M
| $491K | 0.01% |
+40,986
| New | +$442K |
|
|
MRLN
760
DELISTED
Marlin Business Services Corp
MRLN
| $491K | 0.01% |
21,911
+7,671
| +54% | +$190K |
|
761
Peapack-Gladstone Financial
PGC
$822M
| $484K | 0.01% |
+13,810
| New | +$473K |
|
|
PRO
762
DELISTED
PROS Holdings
PRO
| $480K | 0.01% |
18,150
+5,340
| +42% | +$134K |
|
|
LUMO
763
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $477K | 0.01% |
6,541
+522
| +9% | +$43.2K |
|
764
Sierra Bancorp
BSRR
$548M
| $476K | 0.01% |
17,910
+3,710
| +26% | +$99.3K |
|
765
SITE Centers
SITC
$230M
| $474K | 0.01% |
41,040
-470,313
| -92% | -$5.01M |
|
766
Travere Therapeutics
TVTX
$5.33B
| $472K | 0.01% |
+22,400
| New | +$512K |
|
767
Boston Scientific
BSX
$65.8B
| $466K | 0.01% |
+18,810
| New | +$519K |
|
|
ALEX
768
DELISTED
Alexander & Baldwin
ALEX
| $464K | 0.01% |
+16,730
| New | +$653K |
|
769
Conagra Brands
CAG
$7.07B
| $458K | 0.01% |
12,150
+900
| +8% | +$32K |
|
770
Omnicom Group
OMC
$22.7B
| $456K | 0.01% |
6,260
-50,725
| -89% | -$3.64M |
|
|
ECYT
771
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $456K | 0.01% |
106,641
+77,600
| +267% | +$370K |
|
772
Halliburton
HAL
$27.9B
| $454K | 0.01% |
+9,300
| New | +$410K |
|
773
Verastem
VSTM
$532M
| $454K | 0.01% |
12,316
-1,050
| -8% | -$47.4K |
|
774
Rocky Brands
RCKY
$304M
| $450K | 0.01% |
23,803
+5,889
| +33% | +$101K |
|
|
ACHN
775
DELISTED
Achillion Pharmaceuticals
ACHN
| $449K | 0.01% |
+155,900
| New | +$566K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2017 Portfolio in Review
As of Q4 2017, Jacobs Levy Equity Management held 1,134 positions worth $5.69B, up 11% from $5.14B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jacobs Levy Equity Management deployed $263M of net new capital in Q4 2017, opening 196 new positions and adding to 491 existing holdings. Its largest new stake was Yum China: 427,927 shares worth $17.1M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $36.5M trimmed.
- Jacobs Levy Equity Management's largest Q4 2017 buy was Yum China: 427,927 shares worth $17.1M.
- Jacobs Levy Equity Management added most to Bristol-Myers Squibb in Q4 2017, an estimated $35.7M increase.
- Jacobs Levy Equity Management's biggest Q4 2017 reduction was Johnson & Johnson, cutting an estimated $36.5M.
- Jacobs Levy Equity Management fully exited Twenty-First Century Fox, Inc. Class A in Q4 2017, selling an estimated $17.1M.
- Jacobs Levy Equity Management's ten largest holdings make up 12% of its $5.69B portfolio in Q4 2017.
- Jacobs Levy Equity Management opened 196 new positions and closed 159 in Q4 2017.
- Jacobs Levy Equity Management's portfolio value rose 11% quarter-over-quarter to $5.69B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2017, filed 13 Feb 2018.